NR4a knock-down in HER2 CAR-T cells improves T cell longevity and promotes solid tumor eradication

NIAID Data Ecosystem2026-05-02 收录

CAR-T细胞疗法

实体瘤免疫治疗

数据链接：

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE241458 数据链接链接失效反馈

官方服务：

资源简介：

This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

创建时间：

2025-08-01

DataSheet_1_Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial.pdf

精氨酸酶-1靶向肽疫苗

实体瘤免疫治疗

BackgroundArginase-1-producing cells inhibit T cell-mediated anti-tumor responses by reducing L-arginine levels in the tumor microenvironment. T cell-facilitated elimination of arginase-1-expressing c

NIAID Data Ecosystem20

The high affinity Fc receptor provides a unique scaffold for directing T cells against solid cancers

CAR-T细胞疗法

实体瘤免疫治疗

The pioneering design of chimeric antigen receptors T-cells (CAR-T) therapy has revolutionized treatments of refractory lymphomas and demonstrated the potential in reprogramming the immune system. Non

NIAID Data Ecosystem10

Histone marks identify novel transcription factors that parse CAR-T cell subset-of-origin, clinical potential and expansion [RNA-seq]

CAR-T细胞疗法

组蛋白修饰

Chimeric antigen receptor-modified T cell (CAR-T) immunotherapy has revolutionized the treatment of blood cancers. Parsing the genetic underpinnings of T cell precursor quality and subsequent CAR-T ef

NIAID Data Ecosystem00

Dataset from An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.

实体瘤免疫治疗

联合免疫治疗安全性

To evaluate the safety, tolerability, and anti-tumor activity of the combination of durvalumab + tremelimumab or durvalumab alone in different solid tumors.

NIAID Data Ecosystem10

Table_1_Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis.docx

CAR-T细胞疗法

HBV再激活

BackgroundChimeric antigen receptor (CAR) T-cell therapy has emerged as a novel treatment modality for hematologic malignancies and is predicted to experience widespread use in the near future. Howeve

NIAID Data Ecosystem10

NR4a knock-down in HER2 CAR-T cells improves T cell longevity and promotes solid tumor eradication

资源简介：

相关数据集